Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology Press release
Galderma raises approximately USD 1 billion for newly issued shares in a private placement round Press release
Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4 Press release
WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology Press release
Galderma receives FDA approval for its newest hyaluronic acid filler, Restylane® Eyelight™ Press release
AMWC 2023: Data from Sculptra® Cheek Wrinkle and Alluzience® Star Studies reinforce strength of Galderma’s broad aesthetic portfolio Press release
Galderma launches FACE by Galderma™, a cutting-edge aesthetic visualization tool that simulates injectable treatment results in real-time Press release
AAD 2023: Late-Breaking Phase III results demonstrate nemolizumab’s significant impact on prurigo nodularis Press release